Home » FDA Approvals In September

FDA Approvals In September

Oct. 14, 2013

Company	Drug	Indication

Celgene Corp.	Abraxane	Pancreatic adenocarcinoma

Article reprints

BioWorld

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 23, 2024.
AACR 24: Freezing, of all things, is one way to heat cold tumors
BioWorld
“Hot and cold tumors may need different types of immunotherapy,” Jay Berzofsky told the audience as the American Association for Cancer Research’s (AACR) 2024...
Biosimilars coming into their own in China, despite concerns
BioWorld
The timing is ripe for a robust biosimilar market in China, given the rapid increase of novel biologics approved to treat cancer and inflammatory diseases in the...
AACR 2024: New concepts suggest new targets for metastatic disease
BioWorld
Prior to this year’s Annual Meeting of the American Association for Cancer Research (AACR), it had been 14 years since metastasis had been the subject of a...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe

Upgrade your daily dose of biopharma and medtech news

FDA Approvals In September